Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
This study is a Phase 3, multicenter, open-label, trial to evaluate the long-term safety and efficacy of intermittent chronic dosing with AXS-07 in subjects with migraine attacks. Eligible subjects will take AXS-07 following the onset of a migraine. Subjects will be treated for up to 12 months.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has participated in a prior study with AXS-07 for the treatment of migraine
You may not be if
Has previously received any investigational drug or device or investigational therapy within 30 days before Screening, other than AXS-07
Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Clareo Health | Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
